Patents by Inventor HEIKE KEILHACK

HEIKE KEILHACK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EZH2 inhibitors for treating lymphoma
    Patent number: 11951109
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: April 9, 2024
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Danielle Johnston Blackwell
  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20240058348
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: March 23, 2023
    Publication date: February 22, 2024
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • METHOD FOR TREATING CANCER
    Publication number: 20240024331
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Application
    Filed: March 23, 2023
    Publication date: January 25, 2024
    Inventors: Heike KEILHACK, Sarah K. Knutson
  • Method for treating cancer
    Patent number: 11642349
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah K. Knutson
  • EZH2 inhibitors for treating lymphoma
    Patent number: 11642347
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: May 9, 2023
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
  • METHODS OF TREATING CANCER
    Publication number: 20220315566
    Abstract: The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 8, 2022
    Publication date: October 6, 2022
    Inventors: Sarah K. KNUTSON, Natalie WARHOLIC, Heike KEILHACK
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20220281854
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventors: Heike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20220226336
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: November 23, 2021
    Publication date: July 21, 2022
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Kevin W. KUNTZ
  • METHOD OF TREATING CANCER
    Publication number: 20220218714
    Abstract: The present invention relates to methods of treating cancer by administering an EZH2 inhibitor or a pharmaceutical composition thereof to the subject in need thereof
    Type: Application
    Filed: December 21, 2021
    Publication date: July 14, 2022
    Inventors: Heike KEILHACK, Sarah K. KNUTSON
  • Combination therapy for treating cancer
    Patent number: 11370781
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: June 28, 2022
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Kevin Wayne Kuntz
  • EZH2 INHIBITORS FOR TREATING LYMPHOMA
    Publication number: 20220175789
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: November 15, 2021
    Publication date: June 9, 2022
    Inventors: Heike KEILHACK, Sarah Kathleen KNUTSON, Danielle Johnston BLACKWELL
  • METHODS OF TREATING CANCER
    Publication number: 20220160721
    Abstract: The disclosure relates to a method for treating cancer comprising administering a therapeutically effective amount of an EZH2 inhibitor to a subject in need thereof, wherein the cancer is characterized by at least one cancer cell originating from a stem cell, a progenitor cell, or an immature cell and wherein the at least one cancer cell comprises one or more genetic lesion(s) that confer(s) dependence of the cancer cell on an EZH2 function. In certain embodiments, the EZH2 inhibitor of the disclosure is tazemetostat or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 1, 2021
    Publication date: May 26, 2022
    Inventors: Jesse SMITH, Heike KEILHACK, Scott RIBICH
  • EZH2 inhibitors for treating lymphoma
    Patent number: 11202781
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: December 21, 2021
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah Kathleen Knutson, Danielle Johnston Blackwell
  • ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS
    Publication number: 20210379076
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: May 5, 2021
    Publication date: December 9, 2021
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • COMBINATION THERAPY FOR TREATING CANCER
    Publication number: 20210353632
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: April 28, 2021
    Publication date: November 18, 2021
    Inventors: Heike KEILHACK, Roberto PILI
  • METHOD FOR TREATING CANCER
    Publication number: 20210267990
    Abstract: The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.
    Type: Application
    Filed: February 4, 2021
    Publication date: September 2, 2021
    Inventor: Heike KEILHACK
  • METHOD FOR TREATING CANCER
    Publication number: 20210213027
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Application
    Filed: December 21, 2020
    Publication date: July 15, 2021
    Inventors: Heike KEILHACK, Sarah K. KNUTSON
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent number: 11052093
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 6, 2021
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Combination therapy for treating cancer
    Patent number: 11026949
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents (such as tyrosine kinase inhibitors or VEGF/VEGFR inhibitors), particularly anticancer agents such as sunitinib, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: June 8, 2021
    Assignees: Epizyme, Inc., Health Research, Inc.
    Inventors: Heike Keilhack, Roberto Pili
  • METHOD OF TREATING MALIGNANT RHABDOID TUMOR OF THE OVARY (MRTO)/SMALL CELL CANCER OF THE OVARY OF THE HYPERCALCEMIC TYPE(SCCOHT) WITH AN EZH2 INHIBITOR
    Publication number: 20210121470
    Abstract: The disclosure provides a method of treating a malignant rhabdoid tumor in a subject in need thereof including administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In certain embodiments of this method the malignant rhabdoid tumor is small cell cancer of the ovary of the hypercalcemic type (SCCOHT) and the EZH2 inhibitor is tazemetostat (also known as Tazemetostat).
    Type: Application
    Filed: September 3, 2020
    Publication date: April 29, 2021
    Inventor: Heike KEILHACK